Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday?

Core Insights - Aptose Biosciences Inc. announced the approval to escalate the dosage of tuspetinib from 40 mg to 80 mg in the TUSCANY trial based on favorable data from the initial four patients [1][2] - The TUS+VEN+AZA triplet is being developed as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients who cannot receive induction chemotherapy [2][3] - No significant safety concerns or dose-limiting toxicities have been reported in the trial, with all four subjects in the 40 mg cohort remaining in the study [2][4] Trial Details - The TUSCANY trial is enrolling multiple U.S. sites, with an expected total of 18-24 patients by mid-late 2025 [3] - Three patients with wildtype FLT3 completed Cycle 1 without dose-limiting toxicities, with two achieving complete remissions [3][4] - Pharmacokinetic analyses indicate that plasma levels of tuspetinib are unaffected by the addition of azacitidine [4] Market Reaction - Following the announcement, Aptose Biosciences Inc. stock increased by 31.50%, reaching $0.20 [4]